Merck & Co., Inc. (MRK)
Health Care – PHARMACEUTICAL PREPARATIONS
- CEO
- Robert M. Davis
- Headquarters
- United States
- Employees
- 75,000
- Market Cap
- $355.1B
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).
SentiSense also tracks daily options readings for Merck & Co., Inc.: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Merck & Co., Inc. stock analysis, sentiment tracking, and market intelligence on SentiSense.